In the introduction section, the description of the inverse relationship is misleading, where some of the cited studies suggested otherwise and reported a disparity between the interaction of increasing age and BMI.
There is no doubt that comorbidities add to outcome after stroke. However, NIHSS is an independent predictor of outcome in stroke patients. The 3rd paragraph and in line 49, it appears to suggest the contrary.
in the last paragraph of the introduction section, it appears the authors proposed to study the impact of obesity in different groups of stroke severity. However, this is not reflected in the study design Under the method section, clarify the rationale for choosing the stated classification of obesity. It contradicts the WHO recommended classification of obesity in the Asian population.
The authors' choices for normal range contradict the literature and may have skewed their results. For instance, the authors' blood glucose range of 70-180mg/dl as a normal range: previous and recent studies suggest low blood sugar (80-120 mg/dl) is associated with poor outcome, in addition, stress-induced hyperglycemia (particularly in patients non-diabetic) increase poor outcome. In addition, it is unclear how these values were utilized in the statistical analysis or the significance of the values in relation to the study.
Clarify if the selected comorbidities were at the time of diagnosis of the index stroke, during the course of follow up following the index stroke or both. Was there a difference in the frequency of comorbidities in the elderly (>65 years old) and how did "newonset" comorbidities during the follow-up period influence outcome in this group? It will be interesting to test the relationship between new-onset comorbidities and the observation of all-cause mortality in the elderly group.
The abstract conclusion and lines 201-203 could imply that a change in weight (or BMI) was observed in the elderly. If the data is available it would be of interest as it raises important questions on secondary prevention strategies. Alternatively, was a shift in weight due to the acquisition of new-onset comorbidities? Could this explain some of the observed obesity paradox?
Clarify the distribution of stroke severity (NIHSS), stroke mechanisms (cardioembolic, small vessel, large vessel etc) in the entire cohort and/or the BMI categories.
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GENERAL COMMENTS
In the present study authors aim to investigate the association between body mass index (BMI) and mortality due to ischemic stroke among adults aged ≥ 20 years in Korea. The study is interesting, and when the authors would manage to satisfactorily address the comments raised, this manuscript could contribute to the study on body mass index (BMI) and mortality due to ischemic stroke Comment 1) The obesity paradox between body mass index (BMI) and mortality may be due to the criteria for obesity. Have you considered for evaluating for obesity using WC or other body fat measurement variables?
MATERIALS AND METHODS Comment 2) In the sentence "In order to identify potential confounders of the association between BMI and mortality, we reviewed literature data, and…", please give some references to prove this sentence, maybe some meta-analysis references. References Comment 8) Some of the references could be improved to up-todate.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1
________________________________________
In the last paragraph of the introduction section, it appears the authors proposed to study the impact of obesity in different groups of stroke severity. However, this is not reflected in the study design.
We acknowledge that the description of the introduction may mislead the purpose and research design of this study. In response to the reviewer's comments, the sentences and citations in the introduction have been modified in the revised version of the manuscript (page 4, lines 56-78).
Under the method section, clarify the rationale for choosing the stated classification of obesity. It contradicts the WHO recommended classification of obesity in the Asian population.
Body mass index was classified based on the guidelines for the Asian-Pacific population (underweight, less than 18.5 kg; normal weight, 18.5 to 22.9 kg; at risk of obesity or overweight, 23 to 24.9 kg; obese I, 25 to 29.9 kg; and obese II, greater than 30 kg)1. We have clarified this rationale in the revised manuscript (page 5, lines 99-100).
1.
World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment: Sydney: Health Communications Australia, 2000.
The authors' choices for normal range contradict the literature and may have skewed their results. For instance, the authors' blood glucose range of 70-180mg/dl as a normal range: previous and recent studies suggest low blood sugar (80-120 mg/dl) is associated with poor outcome, in addition, stressinduced hyperglycemia (particularly in patients non-diabetic) increase poor outcome. In addition, it is unclear how these values were utilized in the statistical analysis or the significance of the values in relation to the study.
We agree with the reviewer that the term "normal range" is not appropriate. Therefore, we have modified the expression as "a category that could affect prognosis."
As noted by the reviewer, blood sugar levels in stroke patients may differ significantly from that of a normal person, and even without diabetes, hyperglycemia may be experienced, which can also affect the prognosis.
The American Heart Association/American Stroke Association guidelines for acute ischemic stroke recommend treatment for hyperglycemia to achieve serum glucose concentrations in the range of 140 to 180 mg/dL (7.8 to 10 mmol/L)1. The European Stroke Initiative guidelines recommend treatment for glucose level greater than 180 mg/dL (i.e., greater than 10 mmol/L)2. A 2010 meta-analysis found that fasting blood glucose concentration is non-linearly related to vascular risk, with no significant relationships between 3.90 and 5.59 mmol/L. Compared with fasting blood glucose concentrations of 3.90-5.59 mmol/L, hazard ratios (HRs) for coronary heart disease were found to be the following: 1.07 (0.97-1.18) for lower than 3.90 mmol/L, 1.11 (1.04-1.18) for 5.60-6.09 mmol/L, and 1.17 (1.08-1.26) for 6.10-6.99 mmol/L. In people without a history of diabetes, information about fasting blood glucose concentration or impaired fasting glucose status did not significantly improve the metrics of vascular disease prediction when added to the information about several conventional risk factors3.
American Diabetes Association (ADA) workgroup have defined hypoglycemia in patients with diabetes as all episodes of an abnormally low plasma glucose concentration (with or without symptoms) that expose the individual to harm4. They did not identify a specific glucose level that defines hypoglycemia as the glycemic thresholds that induce symptoms (and counterregulatory responses) that vary within and between individuals. The Workgroup identified, instead, an alert glucose level of 70 mg/dL or less (3.9 mmol/L). This glucose concentration approximates the lower limit of the physiologic fasting nondiabetic range, the normal glycemic threshold for glucose counterregulatory hormone secretion, and the highest antecedent low glucose level reported to reduce sympathoadrenal responses to subsequent hypoglycemia. This should alert the patient to the possibility of developing clinically significant hypoglycemia and prompt appropriate actions such as ingestion of carbohydrate or, at the very least, repeated measurements of the glucose level and temporary avoidance of critical tasks such as driving.
On the basis of these guidelines, we set an initial risk of 70-180 mg/dL for the patient. We have clarified such rationale in the revised version of the manuscript (page 6-7, lines 131-136).
Clarify if the selected comorbidities were at the time of diagnosis of the index stroke, during the course of follow up following the index stroke or both. Was there a difference in the frequency of comorbidities in the elderly (>65 years old) and how did "new-onset" comorbidities during the followup period influence outcome in this group? It will be interesting to test the relationship between newonset comorbidities and the observation of all-cause mortality in the elderly group.
All selected comorbidities refer to existing diseases that were present at the time of the index stroke diagnosis. We have clarified this in the revised manuscript (page 6, lines 115-117). Unfortunately, the dataset did not include information about the newly diagnosed disease, except for complications during the follow-up process.
The abstract conclusion and lines 201-203 could imply that a change in weight (or BMI) was observed in the elderly. If the data is available, it would be of interest as it raises important questions on secondary prevention strategies. Alternatively, was a shift in weight due to the acquisition of newonset comorbidities? Could this explain some of the observed obesity paradox?
In the registry, we only collected the weight at admission and did not collect any additional information about body weight changes, so it is not known whether the body weight has changed in the elderly patients or whether there are weight changes due to new-onset comorbidity. However, in elderly patients, obesity is less likely to be a crucial risk factor impeding health compared to younger patients. We acknowledge that our arguments can lead to misunderstandings. Therefore, we modified the corresponding sentences in the revised manuscript (page 2, lines 46-47).
We have added the distribution of stroke severity and stroke mechanisms in the entire cohort and by BMI categories in Table 1 and Table 2. ____________________________________ Reviewer 2 ________________________________________ Comment 1) The obesity paradox between body mass index (BMI) and mortality may be due to the criteria for obesity. Have you considered for evaluating for obesity using WC or other body fat measurement variables?
The reviewer raised a valid point. Unfortunately, the Yonsei Stroke Registry used in this study did not collect WC nor body fat measurement variables. We have included such limitations of our data in the discussion section such that the measurement of fat distribution with, for example, a waist-to-hip ratio or waist circumference, could have been more accurate in assessing the effect of obesity on strokerelated mortality (page 18, lines 326-329).
MATERIALS AND METHODS
Comment 2) In the sentence "In order to identify potential confounders of the association between BMI and mortality, we reviewed literature data, and…", please give some references to prove this sentence, maybe some meta-analysis references.
Per the reviewer's suggestion, we have added some references in the revised manuscript (pages 6, lines 111-116).
Comment 3)
The inclusion of exclusion criteria should be stated in detail. This is a valid point, and we have added the inclusion and exclusion criteria in detail in the revised manuscript (page 5, lines 84-90).
Statistical analysis
Comment 4) Have you did univariate analysis like chi-square or t test or ANOVA between different groups? There is no description in the statistical analysis or results section.
We have modified the manuscript to describe the univariate analyses in the statistical analysis section (page 7, lines 142-144). The results of the univariate analyses are presented in Table 2 , as well as a brief description in the revised manuscript (page 10, lines 184-187).
Comment 5) In my opinion, competing risk analysis should be used to explore the analyze the relationship between BMI and mortality, because there may be some competing events for strokerelated mortality.
Per the reviewer's suggestion, the progression from stroke to stroke-related mortality was assessed using the Fine-Gray competing risk model, treating other-cause mortality as a competing risk. We also performed competing risk analysis with cardiovascular-event-related death as the primary event of interest and non-cardiovascular mortality as a competing event. The methods section has been updated accordingly in the revised manuscript (page 7, lines 152-155), and the corresponding results are shown in Table 3 (which is also presented below).
Comment 6) Have you considered the effect of medication for diseases in all models? How did you adjust for these variables? If the use of medication was not controlled for then the results of the analysis may be biased.
We would like to thank the reviewer for the helpful suggestion. We have modified the methods section to reflect the additional controls of medications in the revised manuscript (page 7, lines 150-151). As the prescribed medication proportions were similar between groups, except statins, as shown in the univariate analysis presented in Table 2 , we performed multivariate analysis, including treatment modalities and statin used as in Table 3 and Table 4 .
Results
Comment 7) In table 1, the NIHSS on admission is not normally distributed, median and interquartile ranges should be used.
We have changed the description of the NIHSS on admission to median and interquartile ranges per the reviewer's suggestion (see Table 1 ).
References
Comment 8) Some of the references could be improved to up-to-date.
We have double checked all references and updated as needed.
VERSION 2 -REVIEW
REVIEWER
Lixin Tao, Associated professor, Epidemiology and medical statistics, the school of public health Capital Medical Univeristy, China REVIEW RETURNED 05-Jul-2019
GENERAL COMMENTS
The author team carried out an sufficient revision to the questions. My personal recommendation is to accept the manuscript after minor revision. The statistical method in the abstract has not been updated.
VERSION 2 -AUTHOR RESPONSE
Reviewer 2
________________________________________
We thank the reviewer for acknowledging the merit of our manuscript. We have update the statistical method in the Abstract per the reviewer's point. We thank the reviewer for pointing this out.
